sellout by board member, page-30

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 30 Last

Share
Profile

Follow
Siva108

8,847 Posts.

586

17/12/16

13:49

Post #: 21409844
Share

Originally posted by crossyaus ↑

Ok fair enough.

I've been out of this for a long time, and won't be back in (not for any money). This puppy has had a great run, but in my opinion reality is starting to catch up with it.

Despite all the ramping on here, if you sit down an read all the RAP market announcements right from listing and try to be as objective as possible, nothing much has really changed about the tech since it first listed.

Sure, it is now moving towards FDA approval (which is still a big IF), but the basic premise and promise of the technology hasn't changed much since listing (note it listed at 2c). As someone who has played in the biotech space for a while, FDA approval can take a very long time, and is by no means guaranteed. I've seen stocks aim to recruit certain numbers of trial patients in the USA, but then never reach the numbers, or it has then taken 12 months to actually get the required number to even commence a trial. Then you go through all the trials and review by the FDA etc. The process can take years. I notice RAP's recent announcement about the FDA trial did not include any timeframe - that's because they don't know how long it will take. I strongly urge anyone investing on the assumption that this trial will be done within 6 months to just spend an hour or so looking at price sensitive announcements regarding FDA trials from any other speccie biotech listed on the asx and just take a look how long it actually takes.

If anyone wants to see a great example of a hyped biotech stock that was going to be the next big thing pending FDA approval which everyone was saying was a sure thing (but then didn't happen), just take at look at the history of PXS.

Combine all the above with Uniquest having dumped everything and now a director selling everything they possibly could (without an official explanation to the market) - this is a high risk investment which is getting closer to coming back to earth each day.

IF this puppy does go down hard, you can't say the warning signs weren't there.

Expand

Try backing up all your talk by doing some research first. MGH clearly stated in house the trials would be complete by June 2017. Don't make false claims if you can't back them up.

RAP Price at posting: 30.5¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 16 more messages in this thread...

First 30 Last

Add RAP (ASX) to my watchlist

sellout by board member, page-30

Top Stories

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News